"Innovative fetal intervention may prove to be a game-changer in many cases, but it is too soon to declare its superiority over current conventional strategies for management of hypoplastic left heart syndrome," says Jack Rychik, M.D., director of the Fetal Heart Program at The Children's Hospital of Philadelphia (CHOP). 

Future prevention and treatment strategies for vascular diseases may lie in the evaluation of early brain imaging tests long before heart attacks or strokes occur, according to a systematic review conducted by a team of cardiologists, neuroscientists, and psychiatrists from Icahn School of Medicine at Mount Sinai and published in the October issue of JACC Cardiovascular Imaging.

The Radiological Society of North America (RSNA) will officially kick off its 100th annual meeting and scientific assembly (Nov. 30 – Dec. 5, McCormick Place, Chicago) with a look back on the role RSNA has played in the history of radiology, brought to life in the RSNA Centennial Showcase.

Enrollment is open for the Dual Epicardial and Endocardial Procedure (DEEP) clinical trial following U.S Food and Drug Administration Approval (FDA). 

Food and Drug Administration gave 510(k) clearance for the HawkOne directional atherectomy system. The latest addition to Covidien’s directional atherectomy portfolio, the HawkOne system provides physicians with an enhanced cutting mechanism to more effectively treat the widest variety of plaque in patients with peripheral arterial disease (PAD).

Shockwave Medical announced that the company will present clinical results from DISRUPT PAD, a single-arm multicenter study evaluating the safety and utility of Lithoplasty balloon catheters for the treatment of peripheral artery disease (PAD), at the Vascular Interventional Advances (VIVA) Annual Conference taking place Nov. 4-7 in Las Vegas.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now